MX2021011688A - Combinaciones utiles en un metodo para tratar sarcoma. - Google Patents

Combinaciones utiles en un metodo para tratar sarcoma.

Info

Publication number
MX2021011688A
MX2021011688A MX2021011688A MX2021011688A MX2021011688A MX 2021011688 A MX2021011688 A MX 2021011688A MX 2021011688 A MX2021011688 A MX 2021011688A MX 2021011688 A MX2021011688 A MX 2021011688A MX 2021011688 A MX2021011688 A MX 2021011688A
Authority
MX
Mexico
Prior art keywords
treating sarcoma
subject
combinations useful
sarcoma
treating
Prior art date
Application number
MX2021011688A
Other languages
English (en)
Inventor
Marla L Weetall
Liangxian Cao
Josephine Sheedy
Robert Spiegel
Original Assignee
Ptc Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ptc Therapeutics Inc filed Critical Ptc Therapeutics Inc
Publication of MX2021011688A publication Critical patent/MX2021011688A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/655—Azo (—N=N—), diazo (=N2), azoxy (>N—O—N< or N(=O)—N<), azido (—N3) or diazoamino (—N=N—N<) compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Un aspecto descrito en la presente solicitud incluye un método para tratar sarcoma en un individuo que lo necesite que comprende, administrar al individuo una cantidad efectiva de un compuesto de molécula pequeña. De manera más particular, otro aspecto descrito en la presente solicitud incluye un método para tratar sarcoma en un individuo que lo necesite que comprende, administrar al individuo una cantidad efectiva del compuesto de molécula pequeña descrito en la presente solicitud en combinación con un agente quimioterapéutico.
MX2021011688A 2019-03-27 2020-03-27 Combinaciones utiles en un metodo para tratar sarcoma. MX2021011688A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962825017P 2019-03-27 2019-03-27
PCT/US2020/025532 WO2020198705A1 (en) 2019-03-27 2020-03-27 Combinations useful in a method for treating sarcoma

Publications (1)

Publication Number Publication Date
MX2021011688A true MX2021011688A (es) 2022-01-24

Family

ID=72609016

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021011688A MX2021011688A (es) 2019-03-27 2020-03-27 Combinaciones utiles en un metodo para tratar sarcoma.

Country Status (11)

Country Link
US (1) US20220152024A1 (es)
EP (1) EP3947379A4 (es)
JP (1) JP2022519930A (es)
CN (1) CN114096537A (es)
AU (1) AU2020248103A1 (es)
BR (1) BR112021019170A2 (es)
CA (1) CA3134648A1 (es)
EA (1) EA202192349A1 (es)
IL (1) IL286647A (es)
MX (1) MX2021011688A (es)
WO (1) WO2020198705A1 (es)

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH593266A5 (es) * 1973-09-20 1977-11-30 Delalande Sa
AU2002228922A1 (en) * 2000-12-12 2002-06-24 Cytovia, Inc. Substituted 2-aryl-4-arylaminopyrimidines and analogs as activators of caspases and inducers of apoptosis and the use thereof
BRPI0720850A2 (pt) * 2006-12-20 2013-01-29 J C Health Care Ltd mÉtodo para administraÇço de doxorrubicina lipossomal peguilada
JP6412503B2 (ja) * 2012-11-21 2018-10-24 ピーティーシー セラピューティクス， インコーポレイテッド 置換逆ピリミジンＢｍｉ−１阻害剤
AU2019340402A1 (en) * 2018-08-17 2021-03-25 Ptc Therapeutics, Inc. Method for treating pancreatic cancer
US20220185795A1 (en) * 2019-03-11 2022-06-16 Ptc Therapeutics, Inc. Compound form having enhanced bioavailability and formulations thereof

Also Published As

Publication number Publication date
EP3947379A1 (en) 2022-02-09
BR112021019170A2 (pt) 2022-03-03
IL286647A (en) 2021-10-31
EP3947379A4 (en) 2022-12-21
US20220152024A1 (en) 2022-05-19
EA202192349A1 (ru) 2022-02-01
JP2022519930A (ja) 2022-03-25
AU2020248103A1 (en) 2021-10-21
WO2020198705A1 (en) 2020-10-01
CN114096537A (zh) 2022-02-25
CA3134648A1 (en) 2020-10-01

Similar Documents

Publication Publication Date Title
PH12020551244A1 (en) Pd-1/pd-l1 inhibitors
MX2019011431A (es) Inhibidores de proteina 1 de muerte celular programada (pd-1)/ligando 1 de muerte programada (pd-l1).
MX2023005160A (es) Compuestos de 4-aminoisoindolina-1,3-diona sustituidos y su uso para el tratamiento de linfoma.
MX2018007944A (es) Composiciones inoculantes estables y metodos para producirlas.
EA202090061A1 (ru) Применение антитела против cd70, argx-110, для лечения острого миелоидного лейкоза
CL2020003276A1 (es) Composiciones y métodos para el tratamiento de hemoglobinopatías y talasemias
MX2020010657A (es) Derivados de oxadiazolina.
MY198004A (en) Antitumoral compounds
MX366765B (es) Agonistas de receptores gamma activados por el proliferador de peroxisoma para el tratamiento de esclerósis múltiple.
PH12019501722A1 (en) Compositions and methods for promoting hair growth with mpc1 inhibitors
MX2019010101A (es) Composiciones y metodos para promover el crecimiento del cabello con inhibidores de mpc1.
EA202191631A1 (ru) Композиции, содержащие бактериальные штаммы
MX2021014309A (es) Composicion para alimentos de animales que contiene los compuestos del componente hexahidro-?-acido y aplicacion de la misma.
CL2021001922A1 (es) Procedimientos para tratamiento de enfermedades con inhibidores de magl.
SV2018005701A (es) Compuestos de 1,3,4-tiadiazol y su uso en el tratamiento del cancer
MX2017009110A (es) Terapia de combinacion para hipertension pulmonar.
WO2021061874A3 (en) Methods and compositions for treating acute myeloid leukemia
MX2021011688A (es) Combinaciones utiles en un metodo para tratar sarcoma.
UY38472A (es) Moduladores de la expresión de foxp3
WO2020055544A3 (en) Method for treating pancreatic cancer
PE20200749A1 (es) Moduladores de la expresion de enac
MX2020005707A (es) Profarmacos de creatina, composiciones y metodos de uso de estos.
MX2019008535A (es) Agonista del ppar gamma para el tratamiento de la enfermedad de huntington.
MX2021010398A (es) Metodo para tratar un mieloma multiple.
WO2020180842A3 (en) Aptamers and use thereof